RxDoctor Payments Data

Crystal Meranto, APRN

Primary Care · Akron, OHNPI 1952033227

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Sanofi at 57.8% of the total. Reporting peaked in 2024 at $4,064 and has fallen 99.0% since, to $39 in 2025. Among primary care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,395in general payments, 2019–2025

Across 105 payments — averaging $60.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$4K
  • Regeneron Healthcare Solutions, Inc.$932
  • AbbVie$852
  • QOL Medical, LLC$217
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$192
  • Johnson & Johnson$126
  • plus $379 from 11 others

What the payments were for

  • Consulting fees$3,40453%
  • Travel & lodging$98915%
  • Food & beverage$2,00231%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,395 in reported general payments places this provider in the 95th percentile of 321 primary care providers in Ohio.

See all primary care providers in Ohio

Medicare billing

Part B allowed, 2024
$4,718
Medicare patients
45
Services billed
51

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase14$48,972
CreonLipase/Protease/Amylase13$40,181
LinzessLinaclotide25$20,537
Omeprazole55$638
Pantoprazole Sodium59$429
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl21$235
Famotidine17$229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$852$60,71838 claims
Aimmune Therapeutics, Inc.Zenpep$52$48,97214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 321 primary care providers in Ohio.

Other primary care in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →